Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2025-09-30
2055-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Currently, there are no available data on the epidemiology or treatment of SITRAME syndrome in France or globally. The importance of this research is to provide an overview of demographic, etiological, and disease progression data for patients with SITRAME syndrome in France. This will allow the establishment of quantitative data on the morbidity and mortality of this rare disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Auvergne-Rhône-Alpes-Limousin Research Database for Still's Diseases in Children and Adults
NCT05055882
Efficacy Study of Two Treatments in the Remission of Vasculitis
NCT00748644
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
NCT01731561
Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease
NCT03770663
Evaluation of Glucocorticoids Plus Rituximab in Patients with Newly-Diagnosed or Relapsing IgA Vasculitis
NCT05329090
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
All the following criteria must be met:
1. Systemic inflammation: at least 1 documented episode of CRP \>5mg/mL during a skin flare
2. Maculopapular rash on the trunk: fixed, non-itchy maculopapular rash on the trunk appearing within hours with clear borders
3. Recurrence in the same areas: at least 3 different episodes
4. Acute: duration less than 8 days
And at least 1 of the following criteria:
1. Fever during flare-ups
2. Flare-ups triggered by infections, vaccinations, or intense physical exercise
3. Fatigue during and/or after flare-ups
4. Associated papular rash
Exclusion Criteria
* Adult patients at the time of inclusion
* Patients not opposed to participating in the research
\- Persons with special protection cannot be included in the study:
* Adults under guardianship or curatorship
* Hospitalized persons without consent and not legally protected
* Persons deprived of liberty
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angele SORIA, PUPH, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP250008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.